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ABSTRACT 
SUPPRESSIVE OLIGODEOXYNUCLEOTIDES AS A TLR ANTAGONIST: 
EFFORTS TO TREAT AUTOIMMUNE DISEASES 
FUAT CEM YAĞCI 
M. Sc. in Molecular Biology and Genetics 
Supervisor: Assist. Prof. Ihsan Gürsel 
September 2007, 61 Pages 
Synthetic oligodeoxynucleotides (ODN) expressing suppressive TTAGGG motifs 
effectively down-regulate the production of proinflammatory and Th1 cytokines 
elicited by a variety of Toll-Like Receptor (TLR) dependent or independent immune 
stimuli. Although initially identified by their ability to block CpG-induced immune 
activation, this class of suppressive ODN (typified by ODN A151) was subsequently 
shown to block multiple forms of immune stimulation and to be effective in the 
prevention and treatment of pathologic autoimmune diseases. Endotoxin-induced 
uveitis (EIU) is an established animal model of acute ocular inflammation. It is 
induced by either systemic or intravitreal administration of lipopolysaccharide (LPS). 
FMF is an autosomal recessive periodic fever disease characterized by recurrent, 
self-limiting, febrile, inflammatory attacks of the serosal membranes such as 
peritoneum, pleura, and synovia. FMF patients in clinical remission are reported to 
have increased baseline inflammation. Present study aims to demonstrate that the 
downregulatory effect of the suppressive DNA could prove benefit to alleviate the 
symptoms associated with i) LPS induced EIU in rabbit or murine models as model 
for local autoimmune disease and ii) Familial Mediterranean Fever a model for 
systemic autoinflammatory disease. Results from this research strongly implicated 
that A151 treated EIU induced animals downregulated IL6 and IL1b cytokine 
secretion or expression as well as chemokines such as or MIP3a, or iNOS levels. Our 
data suggest that FMF patient PBMCs to that of healthy donor`s blood were more 
responsive to TLR ligand stimulation and A151 incubation strongly reversed this 
activation and suppressed certain key cytokine/chemokine levels.  
Keywords: Suppressive DNA, autoimmunity, immunoregulatory effect, TLR, 
antagonizm.
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ÖZET 
TLR ANTAGONİSTİ OLARAK BASKILAYICI 
OLİGODEOKSİNÜKLEOTİDLER: OTOİMMÜN HASTALIKLARI TEDAVİ 
ÇABALARI 
 
Fuat Cem Yağcı  
Moleküler Biyoloji ve Genetik Yüksek Lisans 
Tez Yöneticisi: Yar. Doç. Dr. İhsan Gürsel 
Eylül 2007,61 Sayfa 
  
Baskılayıcı TTAGGG motiflerini içeren sentetik oligodeoksinükleotidler (ODN) 
Toll-Benzeri Almaçlar (TLR) aracılığıyla ya da başka yollarla oluşan proenflamatuar 
ve Th1 sitokinlerin üretimini etkin bir şekilde azaltabilmektedirler. CpG ile 
indüklenen immün aktivasyonu bloke edebilmelerine ek olarak bu baskılayıcı ODN 
sınıfının (ODN A151 tipik bir örneğidir) değişik tipteki immün aktivasyonu bloke 
edebildikleri ve patolojik otoimmün hastalıklardan korunmada ve bu hastalıkların 
tedavisinde etkili oldukları gösterilmiştir. Endotoksin ile indüklenen üveyit (EIU) 
akut oküler enflamasyon için kullanılabilen bir hayvan modelidir. Bu hastalık gram-
negatif bakterilerin tipik yan ürünü olan lipopolisakkaritleri (LPS) sistemik veya göz 
içine uygulayarak oluşturulur. Ailesel Akdeniz Ateşi (FMF), ateş, peritonit, sinovya, 
plörit ve nadiren perikardit ve menenjiti de içeren, serosit ve tekrarlayan kısa 
enflamatuvar ataklar ile karakterize otozomal resesif bir hastalıktır. Bu çalışmada i) 
lokal otoimmün bir hastalık olan, tavsan ve fare hayvan modellerinde LPS ile 
indüklenerek oluşturulan üveite ve ii)  sistemik otoenflamatuvar bir hastalık olan 
Ailesel Akdeniz Ateşine bağlı oluşan semptomların ortadan kaldırılmasında 
baskılayıcı DNA’ların etkili olabileceğinin gösterilmesi amaçlanmıştır. Bu 
araştırmanın sonuçları, EIU oluşturulmuş hayvanlara, A151 uygulanmasının, IL6 ve 
IL1b salımının yanında, MIP3a, ve iNOS seviyelerinin baskılanmasına etkili 
olduğunu kuvvetle işaret etmektedir. Verilerimiz, FMF hastalarının kan hücrelerinin, 
sağlıklı gönüllüler ile karşılaştırıldığında TLR ulaklarının oluşturduğu uyarıya daha 
yüksek seviyede tepki gösterdiğini ve A151 ile inkübasyon sonrası bu aktivasyonun 
bazı önemli sitokin ve kemokinlerin salım ve gen ifadelerinin bastırılabildiğini 
göstermiştir.   
  
Anahtar Kelimerler: Baskılayıcı DNA, otoimmünite, immün düzenleyici etki, TLR, 
antagonizm. 
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INTRODUCTION 
 
 
1.1 The Immune System 
Immune system is a set of mechanisms that protects the host against infection by 
identifying and killing pathogens and tumor cells. The immune system detects various 
pathogens, such as viruses and parasitic worms and distinguishes them from the organism's 
normal cells and tissues (Beck et al., 1996). The immune systems of humans interact in a 
detailed and dynamic network which is consist of many types of proteins, cells, organs, and 
tissues. The vertebrate system adapts over time to recognize particular pathogens more 
efficiently as part of this more complex immune response. The adaptation process creates 
immunological memories and allows even more effective protection during future encounters 
with these pathogens (Litman et al., 2005). 
The immune system has layered defenses of increasing specificity which protects 
organisms from infection. Most simply, physical barriers prevent pathogens such as bacteria 
and viruses from entering the body. The innate immune system provides an immediate, but 
non-specific response if a pathogen breaches these barriers (Litman et al., 2005). The adaptive 
immune system, third layer of protection, takes place if pathogens successfully evade the 
innate response. Here, the immune system adapts its response during an infection to improve 
its recognition of the pathogen. This improved response is then retained after the pathogen has 
been eliminated, in the form of an immunological memory, and allows the adaptive immune 
system to mount faster and stronger attacks each time this pathogen is encountered (Mayer., 
2006). Components of the innate and adaptive immune response is summarized in Table 1.1. 
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Table1.1: Components of the immune system                                                              
(Adapted from: Albertz et al., 2002) 
Innate immune system Adaptive immune system  
Response is non-specific Pathogen and antigen specific response 
Exposure leads to immediate maximal 
response 
Lag time between exposure and maximal 
response 
Cell-mediated and humoral components Cell-mediated and humoral components 
No immunological memory Exposure leads to immunological memory 
Found in nearly all forms of life Found only in jawed vertebrates 
 
 
Both innate and adaptive immunity depend on the ability of the immune system to 
distinguish between self and non-self molecules. In immunology, self molecules are those 
components of an organism's body that can be distinguished from foreign substances by the 
immune system (Smith., 1997). Conversely, non-self molecules are those recognized as 
foreign molecules. (Alberts et al., 2002). The innate immune system is activated by exposure 
to this non-self molecules called pathogen associated molecular patterns (PAMPs) that are 
expressed by a diverse group of infectious organisms. (Metzhitov et al., 1998)   
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1.2 Innate Immunity 
The innate immune system is composed of the cells and mechanisms that defend the 
host from infection by other organisms, in a non-specific manner. This means that the cells of 
the innate immune system recognize, and respond to, pathogens in a generic way, but unlike 
the adaptive immune system, it does not accommodate long-lasting or protective immunity to 
the host (Alberts et al., 2002). 
The major functions of the vertebrate innate immune system include: 
• Recruiting immune cells to sites of infection and inflammation, through the production 
of chemical factors, including specialized chemical mediators, called cytokines.  
• Activation of the complement cascade to identify bacteria, activate cells and to 
promote clearance of dead cells or antibody complexes.  
• The identification and removal of foreign substances present in organs, tissues, the 
blood and lymph, by specialized white blood cells.  
• Activation of the adaptive immune system through a process known as antigen 
presentation (Janeway et al., 2001) 
In contrast to the adaptive system, the innate immune system was relatively neglected for 
many decades until recent discoveries provided a remarkable new understanding of how it 
accomplishes its crucial mission. In order to protect the host from infections the innate 
immune system must accomplish four fundamental tasks. 
• Detection of any infectious agent regardless of it is a virus, bacteria, fungus or parasite. 
• Categorizing the type of invading infectious agent whether it is located intracellularly or 
extracellularly. 
•  Appropriating to the pathogen class activated to either eradicate or at least temporarily 
contain the infection. 
• Inducing the appropriate type of adaptive immune response to eliminate the infection and 
prevent its recurrence. (Krieg., 2006) 
Stimulation of the innate immune response limits the early proliferation and spread of 
infectious organisms via production of immunoprotective cytokines, chemokines and 
polyreactive antibodies (Metzhitov et al., 1998). The main cytokines/chemokines appears 
during the onset of innate immune activation are; TNF-α, IL-1α/β, IP-10, MIP-1α, MIP-3α, 
MCP and Regulated upon activation, normal T-cell expressed, and secreted (RANTES). 
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These mediators can induce fever, apoptosis, neutrophil activation, recruitment of T and B 
cells and induction of inflammation as well as regulating the trafficking of immune effector 
cells to the site of infection.  
Other indispensable cytokines such as; IL-12, (which directs T-helper 1 (TH1) 
differentiation), Type I IFNs (IFN-α and IFN-β; important for anti-viral response), IL-6 
(stimulates and promotes B cell proliferation), IL-15 and IL-18 (helps NK and T cell 
proliferation) and IL-10 (that is known to induce inhibitory/stimulatory effect on other 
immune cells) are involved in the orchestral activation/regulation of innate immunity. 
   
1.2.1 Cells of Innate Immune Response 
All white blood cells (WBC) are called leukocytes. Leukocytes are different from 
other cells of the body in that they are not tightly associated with a particular organ or tissue; 
thus, they function similar to independent, single-celled organisms. Leukocytes are able to 
move freely and interact and capture cellular debris, foreign particles, or invading 
microorganisms. Unlike many other cells in the body, most innate immune leukocytes cannot 
divide or reproduce on their own, but are the products of pluripotential hemopoietic stem cells 
present in the bone marrow (Alberts et al., 2002). 
The innate leukocytes include: Mast cells, natural killer cells, eosinophils, basophils; 
and the phagocytic cells including macrophages, neutrophils and dendritic cells, and function 
within the immune system by identifying and eliminating pathogens that might cause 
infection. (Janeway et al., 2001) 
Mast Cells 
Mast cells are a type of innate immune cell that resides in the connective tissue and in 
the mucous membranes, and are intimately associated with defense against pathogens, wound 
healing, but are also often associated with allergy and anaphylaxis. When activated, mast cells 
rapidly release characteristic granules, rich in histamine and heparin, along with various 
hormonal mediators, and chemokines, or chemotactic cytokines into the environment. 
Histamine dilates blood vessels, causing the characteristic signs of inflammation, and recruits 
neutrophils and macrophages (Viera et al., 1995). 
 
 4
  
Fig 1.1 Mast Cells (Adapted from: Albertz et al., 2002) 
 
Natural Killer Cells 
Natural killer cells, or NK cells, are a component of the innate immune system. NK 
cells attack host cells that have been infected by microbes, but do not directly attack invading 
microbes. For example, NK cells attack and destroy tumor cells, and virally infected cells, 
through a process known as "missing-self". This term describes cells with low levels of a cell-
surface marker called MHC I (major histocompatibility complex)—a situation which can arise 
in viral infections of host cells. They were named "natural killer" because of the initial notion 
that they do not require activation in order to kill cells that are "missing self." (Janeway et al., 
2005). 
Basophils and Eosinophils 
Basophils and Eosinophils are cells related to the neutrophil . When activated by a 
pathogen encounter, basophils releasing histamine are important in defense against parasites, 
and play a role in allergic reactions (such as asthma) (Janeway et al., 2001). Upon activation, 
eosinophils secrete a range of highly toxic proteins and free radicals that are highly effective 
in killing bacteria and parasites, but are also responsible for tissue damage occurring during 
allergic reactions. Activation and toxin release by eosinophils is therefore tightly regulated to 
prevent any inappropriate tissue destruction (Viera et al., 1995).  
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 Fig 1.2 An Eosinophil (Adapted from: Albertz et al., 2002) 
Phagocytes 
The word 'phagocyte' literally means 'eating cell'. These are immune cells that engulf, 
i.e. phagocytose, pathogens or particles. To engulf a particle or pathogen, a phagocyte extends 
portions of its plasma membrane, wrapping the membrane around the particle until it is 
enveloped (i.e. the particle is now inside the cell). Once inside the cell, the invading pathogen 
is contained inside an endosome which merges with a lysosome (Janeway et al., 2001).  The 
lysosome contains enzymes and acids that kill and digest the particle or organism. Phagocytes 
generally search the body for pathogens, but are also able to react to a group of highly 
specialized molecular signals produced by other cells, called cytokines. The phagocytic cells 
of the immune system include macrophages, neutrophils, and dendritic cells (Janeway et al., 
2005). 
Phagocytosis of the hosts’ own cells is common as part of regular tissue development 
and maintenance. When host cells die, either internally induced by processes involving 
programmed cell death (also called apoptosis), or caused by cell injury due to a bacterial or 
viral infection, phagocytic cells are responsible for their removal from the affected site. By 
helping to remove dead cells preceding growth and development of new healthy cells, 
phagocytosis is an important part of the healing process following tissue injury (Alberts et al., 
2002). 
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Macrophages 
ages meaning "large eating cell", are large phagocytic leukocytes, which are 
able to move outside of the vascular system by moving across the cell membrane of capillary 
vessels
Macroph
 and entering the areas between cells in pursuit of invading pathogens. In tissues, 
organ-specific macrophages are differentiated from phagocytic cells present in the blood 
called monocytes. Macrophages are the most efficient phagocytes, and can phagocytose 
substantial numbers of bacteria or other cells or microbes. The binding of bacterial molecules 
to receptors on the surface of a macrophage triggers it to engulf and destroy the bacteria 
through the generation of a “respiratory burst”, causing the release of reactive oxygen species 
such as H2O2 or NO. Pathogens also stimulate the macrophage to produce cytokines and 
chemokines, which summons other cells to the site of infection (Janeway et al., 2001)  
 
Fig 1.3: A Macrophage (Adapted from: Albertz et al., 2002) 
phils, along with two other cell types; eosinophils and basophils, are known as 
granulocytes due to the presence of granules in their cytoplasm, or as polymorphonuclear 
cells (P
Neutrophils 
Neutro
MNs) due to their distinctive lobed nuclei. Neutrophil granules contain a variety of 
toxic substances that kill or inhibit growth of bacteria and fungi. Similar to macrophages, 
neutrophils attack pathogens by activating a "respiratory burst". The main products of the 
neutrophil respiratory burst are strong oxidizing agents including hydrogen peroxide, free 
oxygen radicals and hypochlorite. Neutrophils are the most abundant type of phagocyte, 
normally representing 50 to 60% of the total circulating leukocytes, and are usually the first 
cells to arrive at the site of an infection (Viera et al., 1995). 
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 Fig 1.4: Neutrophils (Adapted from: Albertz et al., 2002) 
 
Dendritic cells (DC) are phagocytic cells present in tissues that are in contact with the 
xternal environment, mainly the skin (where they are often called Langerhans cells), and the 
ning of the nose, lungs, stomach and intestines. They are named for their 
resemb
e characterized 
by high endocytic activity and low T-cell activation potential. Immature dendritic cells 
constan
Dendritic Cells 
e
inner mucosal li
lance to neuronal dendrites, but dendritic cells are not connected to the nervous 
system. Dendritic cells are very important in the process of antigen presentation, and serve as 
a link between the innate and adaptive immune systems (Alberts et al., 2002). 
Dendritic cells are derived from hemopoietic bone marrow progenitor cells. These 
progenitor cells initially transform into immature dendritic cells. These cells ar
tly sample the surrounding environment for pathogens such as viruses and bacteria. 
This is done through pattern recognition receptors (PRRs) such as the toll-like receptors 
(TLRs). TLRs recognize specific chemical signatures found on subsets of pathogens. Once 
they have come into contact with such a pathogen, they become activated into mature 
dendritic cells. Immature dendritic cells phagocytose pathogens and degrade its proteins into 
small pieces and upon maturation present those fragments at their cell surface using MHC 
molecules. Simultaneously, they upregulate cell-surface receptors that act as co-receptors in 
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T-cell activation such as CD80, CD86, and CD40 greatly enhancing their ability to activate T-
cells. They also upregulate CCR7, a chemotactic receptor that induces the dendritic cell to 
travel through the blood stream to the spleen or through the lymphatic system to a lymph 
node. Here they act as antigen-presenting cells: they activate helper T-cells and killer T-cells 
as well as B-cells by presenting them with antigens derived from the pathogen, alongside non-
antigen specific costimulatory signals (Mc Kenna et al., 2005) 
 
                              
 
Fig 1.5: A Dendritic Cell (Adapted from: Albertz et al., 2002)  
 
1.2.2 Pattern Recognition Receptors 
 pathogenic microbes 
during their lifetime. To combat these pathogens effectively, most, if not all, multi-cellular 
innate immune defense mechanisms such as 
antimic
Multi-cellular organisms are constantly exposed to various
organisms have developed some forms of 
robial peptide production and phagocytosis, which rely on detection of the pathogens 
by a set of germline-encoded pattern-recognition receptors (PRRs) (Janeway et al., 2002) To 
initiate immune responses to pathogens, PRRs recognize highly conserved microbial 
structures, so-called pathogen-associated molecular patterns (PAMPs) such as 
lipopolysaccharide (LPS), a major Gram-negative bacterial cell-wall component . The 
proteins of PRR families such as complement, pentraxin, and collectin present in extracellular 
space, play a main role in pathogen opsonization for phagocytic clearance and in activation of 
complement pathways. (Garlanda et al., 2005; Gasque, 2004). Table 1.3 summarizes PRR 
types and their members with their corresponding ligands. 
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Table 1.3: Types of PRRs and their associated members or ligands (Adapted from: Lee et al., 
007)  2
 
 
PRRs on the cell membrane have two major functions: the promotion of microbial 
phagocytosis and the initiation of intracellular signaling pathways (Brown, 2006; Underhill 
nd Ozinsky, 2002). Cytoplasmic PRRs can be grouped into three families: (i) interferon 
(IFN)-i
le 
a
nducible proteins, (ii) caspase-recruiting domain (CARD) helicases, and (iii) 
nucleotide- binding oligomerization domain (NOD)-like receptors (NLRs). IFN-inducib
proteins such as double-stranded RNA (dsRNA)-activated protein kinase (PKR) (Stark et 
al.,1998), and CARD helicases such as retinoic acid-inducible protein I (RIG-I), mediate 
antiviral defense, whereas NLRs primarily mediate antibacterial defense.  
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1.2.3 Toll-Like Receptor Family 
The best understood family of PRRs are the Toll-like receptors (TLRs). (Krieg., 2006).  
 were originally identified in vertebrates on the basis 
of their
e molecules containing PAMP 
includi
a cytoplasmic 
Toll/in
ted from: 
Akira et al., 2004) 
Evolutionarily conserved TLR molecules
 homology with a molecule that stimulates the production of antimicrobial proteins in 
Drosophila melanogaster called Toll. (Trinchieri et al., 2007)  
To date, 11 members of the TLR family have been identified in mammals (Krieg., 
2006). TLR family members recognize and respond to divers
ng lipids, proteins and nucleic acids. TLR1 and TLR6 cooperate with TLR2 to 
discriminate subtle differences between triacyl and diacyl lipopeptides, respectively. TLR4 is 
the receptor for LPS. TLR5 recognizes flagellin. TLR11 recognizes profilin-like protein from 
a parasite. TLR3, 7(8) or 9 were found to recognize nucleic acids such as double stranded 
(ds), single stranded (ss) RNA or ss/ds DNA, respectively. (Ishii et al., 2005)  
TLRs are composed of an ectodomain of leucine-rich repeats (LRRs), which are 
involved directly or through accessory molecules in ligand binding, and 
terleukin-1 (IL-1) receptor (TIR) domain that interacts with TIR-domain-containing 
adaptor molecules (Takeda et al., 2003). Table 1.4 presents TLRs and their ligands. 
 
Table 1.4: Toll-like receptors (TLRs) and some of their important ligands. (Adap
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Table 1.5: Examples of pathogens expressing ligands for multiple TLRs. (Adapted from: 
Trinchieri et al., 2007).  
 
Table 1.6: Chromosomal localization of TLRs.                                                              
 Chromosome 
(Adapted from: http://www.ncbi.nlm.nih.gov/sites/entrez) 
 
TL  Mouse an R Hum
TLR1 5 37.0 cM 4p14 
TLR2 3 E3 4q32 
TLR3 8 B2 4q35 
TLR4 4 33.0 cM 9q32-q33 
TLR5 1 98.0 cM 1q41-q42 
TLR6 5 37.0 cM 4 4p14 
TLR7 X F5 Xp22.3 
TLR8 X F5 Xp22 
TLR9 9 F1 3  p21.3
TLR10 N/A 4p14 
TLR11 14 C1 N/A 
TLR12 4 D2.2 N/A 
TLR 13 X D N/A 
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TLR 1, TLR 2 and TLR 6 
a variety of microbial components. These include 
lipopro
TLR 3 
ice are impaired in their response to dsRNA (Alexopoulou., 2001) 
dsRNA
LR 4 
S recognition. (Poltorak et al., 1998, Hoshino et 
al., 199
TLR2 recognizes 
teins/lipopeptides from various pathogens, peptidoglycan and lipoteichoic acid from 
gram-positive bacteria. (Takeda et al., 2003) There are two aspects proposed for mechanisms 
that could explain why TLR2 recognizes a wide spectrum of microbial components. The first 
explanation is that TLR2 forms heterophilic dimers with other TLRs such as TLR1 and TLR6, 
both of which are structurally related to TLR2 (Takeuchi et al., 2001) Thus, TLR1 and TLR6 
functionally associate with TLR2 and discriminate between diacyl or triacyl lipopeptides. 
(Alexopoulou et al., 2002) The second explanation involves recognition of fungal-derived 
components by TLR2 (15). In this model, TLR2 has been shown to functionally collaborate 
with distinct types of receptors such as dectin-1, a lectin family receptor for the fungal cell 
wall component b-glucan. Thus, TLR2 recognizes a wide range of microbial products through 
functional cooperation with several proteins that are either structurally related or unrelated 
(Gantner et al., 2003). 
 
TLR3-deficient m
 is produced by most viruses during their replication and induces the synthesis of type 
I interferons (IFN-a/b), which exert anti-viral and immunostimulatory activities (Takeda et 
al.,2005). This activation is MyD88 independent and TRIF dependent (Jiang et al., 2004, 
Oshiumi et al., 2003). NK cells are the major players in the antiviral immune response and 
express TLR3 and are activated directly in response to synthetic dsRNA, polyriboinosinic 
polyribocytidylic acid (poly I:C) (Schimdt, 2004). Thus, TLR3 is implicated in the 
recognition of dsRNA and viruses.  
 
T
TLR4 is an essential receptor for LP
9) Toll-like receptor 4 was identified as the first human homologue of the Drosophila 
Toll. This extracellular TLR is expressed in variety of cell types, most predominantly in 
macrophages and DCs (Medzhitov et al., 1997). The extracellular domain of TLR4 that 
contain over 600 amino acids is highly polymorphic compared with the transmembrane and 
intracellular domain of the protein (Smirnova et al., 2000) This TLR4 polymorphism 
contributes to species-specific differences in recognition of LPS, the prototypic TLR4 ligand 
(Hajjar et al., 2002). The intracellular TIR domain, which is composed of three highly 
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conserved regions, contains 150 amino acids. The TIR domain modulates protein–protein 
interactions between the TLRs and signal transduction elements (O’Neill et al., 2000). 
Recognition of LPS by TLR4 is complex and requires several accessory molecules. LPS is 
first bound to a serum protein, LPS-binding protein (LBP), which functions by transferring 
LPS monomers to CD14. MD-2 act as an accessory protein and is required for LPS mediated 
signaling through TLR(Wright, 1999). In addition to LPS, TLR4 recognizes several other 
ligands, such as lipoteichoic acid, heatshock proteins (HSP), and EDA in fibronectin (Li et al., 
2007). Similar to TLR3 MyD88 independent TLR4 activation is also lead to Type I IFN 
production this is known as the TRIF pathway (Uematsu et al., 2007). 
 
TLR 5 
onstrated that flagellin was the component of Listeria culture 
superna
LR 7 and TLR 8 
LR8 are structurally highly conserved proteins (Akira et al., 2006). The 
synthet
It has been dem
tants that activated TLR5, and subsequent work in many laboratories confirmed this 
finding for flagellins from various organisms (Hayashi et al., 2001). To date, flagellin is the 
only known activator of TLR5 (an extracellular member of the TLR family) and until recently 
flagellin- induced inflammation was believed to be fully dependent on TLR5 expression. It 
has been shown in various studies  that TLR5 is responsible for flagellin-induced responses in 
epithelial cells, endothelial cells, macrophages, dendritic cells (DCs), and T cells (Steiner., 
2007) 
 
T
TLR7 and T
ic imidazoquinoline-like molecules imiquimod (R837) and resiquimod (R848) have 
potent antiviral activities and are used clinically for the treatment of viral infections. Murine 
TLR7 and human TLR7 and TLR8 recognize imidazoquinoline compounds (Hemmi et al., 
2002, Ito et al., 2002). Furthermore, murine TLR7 has been shown to recognize guanosine 
analogs such as loxoribine, which has antiviral and anti-tumor activities (Akira et al., 2006). 
Recently, TLR7 and human TLR8 have been shown to recognize guanosine- or uridine-rich 
ssRNA from viruses such as human immunodeficiency virus, vesicular stomatitis virus, and 
influenza virus (Diebold et al., 2004, Heil et al., 2004). Similar to TLR3, TLR9, TLR7/8 
constitutes the members of the nucleic acid sensing endozome- associated receptors. 
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TLR 9 
NA, which contains unmethylated CpG motifs, is a strong activator of host 
immun
s specific for signature molecules of extracellular pathogens such as 
lipopol
 activation of innate immunity by most of the members of TLR family 
involve
dependent and independent signaling cascade mediated by endosomal/extracellular TLRs. 
Bacterial D
ity. In vertebrates, the frequency of CpG motifs is remarkably reduced, and the 
cystosine of CpG motifs are highly methylated, in addition to CpG supression leading to 
abrogation of immunostimulatory activity. TLR9 mediates the recognition of CpG DNA 
(Hemmi et al., 2000). CpG DNA motifs are also found in the genomes of DNA viruses. 
Mouse pDCs produce IFN-α_by recognizing the CpG containing DNA of herpes simplex 
virus type 2 (HSV-2) via TLR9 (Lund et al., 2003). TLR9-deficient mice were also shown to 
be susceptible to mouse cytomegalovirus infection, suggesting that TLR9 induces antiviral 
responses by sensing the CpG containing DNA of DNA viruses (Tabeta et al., 2004, Krug et 
al., 2004). 
TLR
ysaccharide, lipopeptides, peptidoglycan, flagellin and zymosan are expressed at the 
cell surface, whereas TLRs that recognize intracellular pathogens are expressed within the 
subcellular compartments of innate immune cells and these TLRs are specific for nucleic 
acids (Krieg., 2006). One controversial exception is the protein hemozoin (HZ) extracted from 
plasmodium (Coban et al., 2005). On the contrary, Parroche et al reported that “Malaria 
hemozoin is immunologically inert but radically enhances innate responses by presenting 
malaria DNA to Toll-like receptor 9” (Parroche et al., 2007). The endosomal localization of 
TLR9 allows efficient detection of invading viral nucleic acids, while preventing ‘accidental’ 
stimulation by CpG motifs within self DNA. (Barton et al., 2005).  
            
Cellular
s a signaling cascade that proceeds through myeloid differentiation primary response 
gene 88 (MyD88), interleukin-1 (IL1) receptor-activated kinase (IRAK) and tumor necrosis 
factor receptor (TNFR)-associated factor 6 (TRAF6), and culminates in the activation of 
several transcription factors , including nuclear factor –κB (NF- κB) , activating protein 1 
(AP1), CCAAT/enhancer binding protein (CEBP) and cAMP-responsive element binding 
protein (CREB) (Takeshita et al., 2000, Hacker et al., 2000) As a result of TLR stimulations 
by cognate ligands, pro-inflammatory response genes including cytokines such as TNFα, IL-
6, IL-12 and co-stimulatory molecules are induced via activation of NF-κB and MAP kinases, 
whereas Type-1 IFN and their inducible genes are induced via interferon regulatory factors 
(IRF) 3 or 7 (Ishii et al., 2005). Figure 1.6 summarizes the major key players in the MyD88 
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Fig 1.6: Summary of the MyD88 dependent/independent signaling pathway initiated by TLRs 
(Adapted from: Akira et al., 2004) 
d allow the effective presentation of microbial antigens to 
cells of
Microbial TLR ligands can activate dendritic cells (DCs), macrophages, and other 
antigen-presenting cells (APCs) an
 the adaptive immune system (Rothstein., 2006). Activated DCs produce cytokines and 
chemokines that will be toxic to pathogen and instruct other immune cells about the nature of 
antigens.  Afterwards, they will present an antigen with their optimally loaded major 
histocompatibility complex (MHC) class I and MHC class II molecules to T and B cells (Lee, 
2007). Activated T and B cells expressing T cell receptor (TCR) and B cell receptor (BCR) 
will migrate to the infected area of the body on account of the production of chemokines 
(Luster, 2002). These cells rapidly differentiate into effector cells whose main role is to get rid 
of the infection. This, they mainly succeed without recourse to adaptive immunity. 
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1.3 The effects of DNA on Immune System 
ucleic acids such as DNA and RNA are essential components of all living organisms 
(Ishii e hin the nuclear or mitochondrial 
membr
ffected by DNA in multiple and complex manner. Bacterial 
unostimulatory CpG motifs that trigger a protective innate 
immun
1/4, TRAF6 and subsequently the MAP kinase 
signalin
N
t al., 2005) DNA is normally tightly sequestered wit
ane in eukaryotes, the cell wall in bacteria, or the envelope in viruses. However, 
following microbial infection or failure of host DNA clearance, DNA can be released from 
microbes or damaged host cells. Such DNA is detected by, and modulates, the innate immune 
system (Akira et al., 2006, Nagata et al., 2005). Such phenomenon had often been ignored, 
but are now in the limelight after the recent discovery of Toll-like receptors (TLR) 
(Medzhitov et al., 2002, Akira et al., 2004) Structure- or sequence-dependent immune 
recognition of nucleic acids by TLR were shown to play an important role in both innate and 
adaptive immune responses to infectious organisms including bacteria, virus and parasites 
(Wagner., 2004, Iwasaki et al., 2004) Novel therapeutics including nucleic acid-based 
agonists/antagonists via TLR-mediated immunomodulation are being developed for multiple 
therapeutic applications to prevent or treat infectious diseases, allergic disorders and cancer 
(Krieg., 2002, Klinman., 2004) 
Immunostimulatory CpG ODN 
The immune system is e
DNA contains unmethylated imm
e response via TLR9  that contains the proliferation and maturation of B cells, NK 
cells and dendritic cells and secretion of various cytokines, chemokines and/or polyreactive Ig 
(Klinmann et al., 2003). CpG DNA binds to, and is taken up by immune cells through 
endocytic pathways, then co-accumulates with TLR9 in phagosome-like vesicles, a process 
controlled by PI3 kinase (Klinman., 2004). 
 Interaction of CpG DNA with TLR9 triggers the recruitment of the MyD88 adaptor 
molecule, followed by activation of IRAK
g cascade, culminating with nuclear translocation of NF-κB. CpG DNA-mediated 
activation of the innate immune system is characterized by B cell proliferation, dendritic (DC) 
maturation, NK cell activation and production of pro-inflammatory cytokines (such as IL-6, 
12 and Type-I and Type-II IFN), chemokines (such as MCP-1, IP-10, MIP-1α,β,) and 
immunoglobulins. Single stranded oligodeoxynucleotides (ODN) containing unmethylated 
CpG motifs (CpG ODN) mimic immunostimulatory activity of bacterial DNA. Impressive 
immunostimulatory activity of CpG ODN is being recorded for future use in a variety of 
therapeutic purposes (Klinman., 2004). 
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There are three known types of CpG ODN: D-type (also known as A-class), K-type 
(also known as B-class) and the recently described C-class, all of which possess unmethylated 
CpG dinucleotides and require TLR9 to activate the immune system. (Klinman., 2004, Krieg., 
2006) These 3 types of ODN possess CpG dinucleotides, but their flanking sequences and 
compositions are different. For example, K-type ODN contain multiple CpG motifs, whereas 
D-type ODN have one CpG with palindromic flanking sequences. D-, but not K- nor C-type 
ODN have a poly-G (5-6 bases) tail at the 3’-end, which may account for their distinct 
activity. K- and C- but not D type ODN have phosphorothioate linkage between all 
nucleotides. D-type ODN stimulate plasmacytoid DC (pDC) to secrete large amounts of IFNa, 
whereas K-type ODN strongly stimulate B cells to proliferate and to secrete IL-6 and IgM. C-
type ODN show a combined activity of K- and D-type ODN, but to a lesser extent (Ishii et al., 
2005). 
      
 
Fig 1.7: TLR9 dependent signaling pathway (Adapted from: Klinman et al., 2004)  
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Class III PI3K (PI3K (III)), EEA1, and Rab5 mediate the trafficking and maturation of 
endoso
 
ich 
can con  
issue damage, inflammation must be waned and terminated with 
tissue 
immun
mes containing CpG DNA and TLR9, by which TLR9 transduces intracytoplasmic 
signal. The signal initiates with the recruitment of MyD88 to the TIR, which then activates 
IRAK-TRAF6-TAK1 complex. This leads to the activation of both MAPKs (JNK1/2 and 
P38) and IKK complex, culminating upregulation of transcription factors including NF-kB
and AP-1. Raf1-MEK1/2-ERK1/2-AP-1 pathway is involved in CpG DNA-induced IL-10 
production in macrophages. The alternative pathway mediated by class I PI3K (PI3K (I))-
PDK1-AKT/PKB is also suggested to be involved in TLR9-mediated cellular activation. 
Recently, Gursel et al., discovered the co-receptor CXCL16 expressed on pDC wh
tribute to discribe the dichotomy of response between D and K types. In this work, her
group demonstrated for the fist time that a type of surface expressed scavenger receptor is 
required for the D-ODN activation of pDC to secrete robust IFNα (Gursel et al., 2006). 
Immunosuppressive ODN 
During infection or t
remodeling and healing. In this case, a negative feedback system of innate immune 
activation occurs via several inhibitory signals (Ishii et al., 2005). CpG-driven immune 
activation can exacerbate inflammatory tissue damage, or increasing sensitivity to 
autoimmune diseases or toxic shock. Similarly, other immune responses designed to protect 
the host can have deleterious consequences if not adequately regulated. (Klinman et al., 2005) 
Recent evidence suggested that host DNA contained some antagonistic elements to the 
ostimulatory effect in their DNA or against pathogen derived CpG rich DNA, possibly 
suppressing DNA-driven immunostimulation (Ishii et al., 2004). Neutralizing or suppressive 
motifs can selectively block CpG-mediated immune stimulation (Krieg et al., 1998) 
Suppressive motifs are rich in poly-G or GC sequences, and optimal motifs are surprisingly 
identical to telomere sequences (with a repeat of TTAGGG), which are present in DNA of 
mammals, but not in bacteria (Gursel et al., 2003) Suppressive activity of ODN also correlates 
with their ability to form higher structures such as G-tetrads (Gursel et al., 2003).  Recent 
studies indicated that suppressive ODN did not interfere with binding or uptake of CpG ODN 
(Yamada et al., 2002) Rather, they blocked either TLR9 binding or assembling of CpG DNA 
or the signaling cascade initiated by CpG DNA upstream of NF-κB translocation to the 
nucleus (Gursel et al., 2003, Yamada et al., 2002). Previous research established that 
suppressive ODN can down-regulate inflammatory responses that are deleterious to the host 
(Zeuner et al., 2002, Dong et al., 2004). Suppressive ODN block the production of Th1 and 
proinflammatory cytokines induced by bacteria in vitro. In vivo, they inhibit the development 
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of organ-specific autoimmune diseases, such as arthritis and experimental autoimmune 
encephalomyelitis (EAE) or lung inflammation. (Zeuner et al., 2002, Dong et al., 2004, Ho et 
al., 2003, Yamada et al., 2004) 
The effect of suppressive ODN on other inflammatory events that are TLR9 
indepen
1.4 Endotoxin Induced Uveitis 
 time that the eye has a special relationship with the 
immun
del of acute ocular inflammation 
induced
dent has been explored. Suppressive ODN were shown to bind STAT1 and STAT4, 
thereby inhibiting their downstream signaling cascade that is independent of TLR9 signaling, 
resulting in reduced incidence of LPS-induced endotoxic shock and Th2 biased adaptive 
immune responses (Shirota et al., 2005, Shirota et al., 2004). It is quite interesting that 
suppressive sequences in self-DNA may play a role in neutralizing exacerbating inflammation 
or modulating both innate and adaptive immune responses in a TLR9 independent manner, 
thereby providing potential therapeutic uses as natural anti-inflammatory agents or Th2 
inducing adjuvants. 
 
It has been known for a long
e system, known as immune privilege (Simson., 2006). The immune privilege of the 
eye is a complex phenomenon, involving many layers and mechanisms: (i) physical barriers 
prevent entry and exit of larger molecules such as proteins from the eye; (ii) cell-bound and 
soluble immunosuppressive factors within the eye inhibit the activity of immune-competent 
cells that may gain entry; and (iii) protein antigens released from a damaged eye elicit deviant 
systemic immunity that limits the generation of proinflammatory effector cells (Streilein., 
2003). Acting in concert, these elements serve to create a milieu designed to protect the 
delicate visual axis from damage by inflammatory processes that in any other organ would not 
carry adverse functional consequences. Based on accumulated evidence from rodent studies, it 
is widely accepted that breakdown of immune privilege contributes to bystander damage from 
infection, to rejection of corneal grafts, and to development of uveitis. However, the ease with 
which it is possible to elicit autoimmunity in experimental animals to antigens originating 
from the retina puts in question the role of immune privilege as an effective barrier against 
ocular autoimmunity (Niederkorn., 2006, Streilein., 2003). 
Endotoxin-induced uveitis (EIU) is an animal mo
 by the administration of lipopolysaccharide (LPS), a component of Gram-negative 
bacterial outer membranes. Because uveitis frequently leads to severe vision loss and 
blindness with retinal vasculitis, retinal detachment, and glaucoma, it is important to elucidate 
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further the mechanisms in the development of ocular inflammation (Rosenbaum et al., 1980, 
Hoekzema et al., 1992) Uveitis can have a variety of underlying causes. For instance, acute 
anterior uveitis is often associated with Behcet’s disease, ankylosing spondylitis, Reiter’s 
syndrome, and human leukocyte antigen (HLA) B27-associated uveitis as well as other 
systemic inflammatory diseases (Chang et al., 2005) 
LPS enhances the expression of various inflammatory mediators, such as IL-6, 
(Hoekz
 
reduce 
.5. Familial Mediterranean Fever 
group of disorders characterised by seemingly 
unprov
ilial Mediterranean Fever (FMF) is the most well known and best characterized of 
the HP
ema et al., 1992, Ohta et al., 2005) TNF-α, (Koizimi et al., 2003) and MCP- 1, (Mo et 
al., 1999) as well as the production of nitric oxide (Bellot et al., 1996) all of which contribute 
to the development of EIU, resulting in the breakdown of the blood–ocular barrier and in the 
infiltration of leukocytes. For the first phase of leukocyte infiltration, cell adhesion to vascular 
endothelium is essential, in which adhesion molecules play major roles (Springer et al., 1993). 
Among various adhesion molecules, intercellular adhesion molecule (ICAM)-1 and its 
receptor, lymphocyte function-associated antigen (LFA)-1, are necessary for the development 
of EIU (Springer et al., 1993, Whitcup et al., 1993). Although EIU was originally used as a 
model of anterior uveitis, increasing evidence shows that it also involves inflammation in the 
posterior segment of the eye with recruitment of leukocytes that adhere to the retinal 
vasculature and infiltrate the vitreous cavity (Miyamoto et al., 1996, Yamashito et al., 2003). 
Current therapies for uveitis include corticosteroids and chemotherapeutic agents to
inflammation (Dunn., 2004). However, the grave side effects of these drugs, such as 
increased intraocular pressure (Moorthy et al.,1997) or cytotoxicity (Lightman., 1997), limit 
their use (Dunn., 2004, Moorthy et al.,1997). Therefore, a new therapeutic strategy is urgently 
needed (Adamus et al., 2006, Avunduk et al., 2004). 
 
1
Autoinflammatory diseases are a 
oked inflammation in the absence of high-titre autoantibodies or antigen specific T 
cells (Stojanov et al., 2005). They include the hereditary periodic fever syndromes (HPF) and 
are thought to be caused by disturbances in the regulation of innate immunity (Kastner., 
2005).  
Fam
Fs. The mutated gene, Mediterranean Fever (MEFV), encoding pyrin/marenostrin 
protein, was identified in 1997 and found to be predominantly expressed in neutrophils, 
monocytes and eosinophils but not in lymphocytes (Aksentijevich et al., 1997, Bernot et 
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al.,1997) , suggesting a potential functional role in the regulation of inflammation. The vast 
majority of FMF-associated mutations are located in the B30.2 serine-proline-arginine-
tyrosine (SPRY) domain, at the carboxy terminus of the protein (Gumucio et al., 2002). This 
domain is thought to function as a ligand binding or signal transduction domain, and 
therefore, B30.2 mutations may cause delayed apoptosis and inflammation by the reduced 
ability of pyrin to moderate IL-1β activation [Gumucio et al., 2002, Stojanov et al.,2005). 
There are over 100 variants in the MEFV gene recorded to date (de Menthiere et al., 2003), 
and the majority are disease associated mutations. The three most commonly reported 
mutations are M694V, M680I and V726A (Eisenberg et al.,1998). 
Levels of blood cytokines and acute phase reactants have been measured in FMF 
patient
ent absence of a C5a/interleukin-8 (IL-
8) inhi
e 
FMF patients exhibit increased levels of serum IL-6, IL-8, soluble ICAM-1 and 
soluble
s and the results provide additional enticing clues. Typical laboratory findings during 
an attack include leukocytosis, an elevated erythrocyte sedimentation rate and increased acute 
phase reactants (e.g. serum amyloid A, fibrinogen, C-reactive protein) (Sohar et al., 1967, 
Baykal et al., 2003, Gang et al., 1999). Several studies have now shown that these 
components are also elevated between attacks in FMF patients [Baykal et al., 2003, Korkmaz 
et al., 2002, Poland et al., 2001 , Duzova et al., 2003). 
A striking finding in FMF patients is the appar
bitor activity in the serosal fluids of FMF patients (Matzner et al., 1984). The activity 
of this inhibitor is also defective in primary fibroblast cultures derived from the serosa of 
FMF patients (Matzner et al., 2000). The anaphylotoxin C5a is a powerful chemoattractant for 
many leukocytes (e.g. neutrophils, monocytes) and acts as a pro-inflammatory mediator in a 
during infection (e.g. it stimulates increased vascular permeability and monocyte/granulocyt
oxidative burst responses) (Kohl., 2001). The chemokine IL-8 is also a potent 
chemoattractant, primarily for neutrophils, although it is also implicated in monocyte 
adhesion (Ohlson et al., 2002). The C5a/IL-8 inhibitor identified by Matzner and colleagues is 
a serine protease that inactivates both C5a and IL-8 via direct proteolysis. The hypothesis in 
regards to FMF, therefore, is that even with a normally insignificant inflammatory insult (e.g. 
minor trauma secondary to running) the absence of the C5a/IL-8 inhibitor allows IL-8 and 
C5a to accumulate, inducing a massive neutrophil chemotaxis that results in an inflammatory 
crisis. 
 TNF receptors p55 and p75 relative to controls (Kiraz et al., 1998, Baykal et al., 
2003). However, the findings seem to vary depending on the timing of cytokine measurement. 
It has been suggested that later stages of the attack may be characterized by depleted stores of 
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TNF-α due to a previous massive release of this cytokine from monocytes at the onset of the 
attacks (Schattner et al., 1991, Schattner et al., 1996). Gang et al. (1999) measured IL-1β and 
IL-1 receptor antagonist levels and suggested that these components are unaltered during 
attacks (Gang et al., 1999). But in another study, mRNA levels for TNF-α, IL-1β, IL-6 and 
IL-8 were all increased relative to controls in circulating leukocytes of attack-free FMF 
patients (Notarnicola et al., 2002). Finally, Aypar et al. (2003) reported high levels of IFNγ 
production in FMF patients. Interestingly, the percentage of IFNγ positive T cells was also 
increased in FMF patients both during and between attacks (Aypar et al., 2003). Since the 
percentage of IL-4 positive T cells (Th2 cells) was not increased, these authors concluded that 
inflammation in FMF shows a Th1 polarization. 
Colchicine is one of the most important drug used in the treatment of FMF. The 
remark
cks, and 
.6. Aim and Strategy 
response triggered by several TLR ligands can improve host 
surviva
ne activation induced by multiple TLR 
ligands
able therapeutic response of FMF to colchicine was identified by Goldfing in 
1972 (Goldfing., 1972). It greatly reduces the frequency and intensity of clinical atta
by effectively suppressing inflammation generally in this particular disease, very largely 
prevents the development of amyloidosis (Zemer et al., 1996). However, despite the efficacy 
of colchicine, amyloidosis remains an important cause of morbidity and mortality in FMF, 
most likely relating to lack of such treatment, insufficient dosing, poor compliance and, in a 
small proportion of cases, perhaps approximately 5%, a genuine lack of response (Ben-Chetrit 
et al., 1998). No other therapy is of proven long-term efficacy in FMF. Therefore, a new 
therapeutic strategy is needed. 
 
1
The innate immune 
l following pathogen challange. Yet unchecked stimulation of the innate immune 
system can cause tissue damage, autoimmune disease, and even death.  Krieg et al were the 
first to demonstrate that “neutralizing” ODN containing G-run sequences selectively inhibited 
CpG-induced immune activation (Krieg et al., 1998).  
Suppressive ODN were found to limit the immu
 in vitro (Klinman et al., 2003, Zhu et al., 2002). In vivo, suppressive ODN 
ameliorated a variety of organ-specific autoimmune diseases, including inflammatory 
arthritis, rheumatoid arthritis, and EAE (Zeuner et al., 2002, Dong et al., 2004 , Ho et al., 
2003). 
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This thesis is designed to broaden the immunosuppressive spectrum of a candidate 
TLR ligand antagonist A151 ODN. The first part of the thesis will be devoted to demonstrate 
the beneficial role of suppressive ODN on experimental uveitis. For this, we have selected to 
work with two different animal models. Upon parenteral or local LPS administration, EIU 
was established either in rabbit or in murine models respectively, as a local autoimmune 
disease.In the second part, human Familial Mediterranean Fever was selected as  a model for 
a systemic autoinflammatory disease. 
On EIU model, different sites from rabbit and/or mouse will be analyzed  and 
downreglatory effect of A151 on the gene expression or protein secretion levels will be 
assessed either by PCR or by ELISA respectively. Changes in mRNA message of IL1β, IL6, 
IL-15, IP10, iNOS, MIP3α will be checked by PCR method. ELISA assay will be performed 
on one of the key proinflammatory cytokine, namely, IL6.  
In the second part of the study, we will isolate peripheral blood mononuclear cells 
(PBMCs) from FMF patients and healthy controls. Whether there is a background TLR (1-10) 
expression difference or baseline activity of certain proinflammatory or Th1-based cytokine 
expression levels (such as IL1β, IL6 and TNFα) between FMF and healthy donors will be 
determined. Then, these cells will be subjected to i) PGN for TLR2, ii) LPS for TLR4, iii) 
pI:C for TLR3, iv) R848 for TLR7/8 stimulations either alone or in combination with A151, 
and suppressive ability to downregulate the innate immune response initiated by these ligands 
will be documented.  
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MATERIALS AND METHODS 
 
2.1. MATERIALS 
All cell culture media components were from Hyclone (USA) unless otherwise stated. 
Cytokine pairs for ELISA assays were from Endogen (USA) unless otherwise stated. TLR 
ligands; phosphorothioate backbone modified K-Type (or Type B) ODN, ODNK23: 5`-
TCGAGCGTTCTC-3` and D-type (type A) mixed backbone ODN (phosphorothioate-
phosphodiester- phosphorothioate: PS-PO-PS) ODND35 5`-GGtgcatcgatgcaggggGG (lower 
case letters are PO bases) and suppressive ODN A151 5`-
TTAGGGTTAGGGTTAGGGTTAGGG-3` were obtained from Alpha DNA (Montreal, 
Canada),  PGN (isolated from B.subtilis; Fluka, Switzerland), pI:C (Amersham, UK), LPS 
(isolated from E.coli; Sigma, USA), ,  phosphorothioate backbone modified synthetic R848 
(Invivogen, USA). TRIdity G (AppliChem, Germany) was used for RNA isolation. cDNAs 
were synthesized by DyNAmoTM cDNA Syntesis kit (Finnzymes, Finland) according to the 
manufacturer’s protocol.  
For the information on standard solutions, buffers, and other cell culture media please 
refer to Appendix 1 for details. 
 
2.2. METHODS 
 
2.2.1. The Maintenance of the Animals 
Adult female BALB/C mice were used for the experiments. The animals were kept in 
the animal holding facility of the Department of Molecular Biology and Genetics at Bilkent 
University under controlled conditions at 22o C with 12 hour light and 12 hour dark cycles. 
They were provided with unlimited access of food and water. Our experimental procedures 
have been approved by the animal ethical committee of Bilkent University (Bil-AEC No: 
06/027). 
 
2.2.2. Endotoxin Induced Uveitis  Model 
40 Ten week old female BALB/c mice were obtained from the animal holding facility of the 
Department of Molecular Biology and Genetics at Bilkent University. The mice were injected 
i.p with 250-300 ug of ODN (a dose previously found to prevent the development of 
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autoimmune disease) and/or LPS (30-100 ug in 200ul of PBS). Clinical assessment of EIU 
was based on redness and discharge of the eye, cloudy anterior chamber, and lack of papillary 
reactivity to the light. Control mice were injected with 200ul PBS i.p. Mice were killed at 24 
hours after injection. Eyes were enucleated and used for cytokine expression assays. Spleens 
were removed and incubated on tissue culture plates for 4 hrs and supernatants were collected 
for cytokine determination by ELISA.  IL-6 was measured as an indicator of EIU response. 
The other half of the spleen was used to extract total RNA for further cytokine/chemokine 
message expression analysis by RT-PCR.  
In another experiment, Rabbits (3-4 animal/groups, 1500 gm each housed in Ankara 
Hospital animal facility, Cebeci, Ankara) were separated in to different treatment groups and 
EIU was initiated via intraocular LPS injection (100 ng) with or without A151 suppressive 
ODN. Eyes were removed and further analyses was conducted on them.    
 
2.2.3. Cell Culture 
 
2.2.3.1. Spleen and Ocular Cell Preparation 
Spleens and eyes were removed from the BALB/C female mice after cervical 
dislocation. Single cell suspensions were obtained by smashing of spleens and eyes with the 
back of the sterile syringes by circular movements in the 2% FBS supplemented regular 
RPMI. The cells were washed 2-3 times at 1500 rpm for 10 mins. The cell pellet was gently 
dislodged with fresh media, the tissue debris was removed and finally the cell suspensions 
were counted and adjusted to 2-4x106/ml unless otherwise stated. 
 
2.2.3.2. Peripheral Blood Mononuclear Cell Preparation 
50 ml blood collected from each donor with heparinized syringes and seperated into 
two 50ml falcon tubes from syringes. 25 ml blood slowly layered on the top of each 15 ml 
histopaque layer and centrifuged 30 minutes at 1800 rpm at room temperature (RT) setting the 
break off. The opaque interface containing mononuclear cells slowly aspirated into a new 50 
ml falcon tube by using a sterile Pasteur pipette. Tubes were then filled with %2 FBS 
supplemented regular RPMI-1640 and centrifuged 10 minutes at 1800 rpm at RT. Supernatant 
removed by using a sterile pipette and pellet resuspended in %2 regular RPMI-1640 and 
centrifuged 10 minutes at 1800 rpm at RT. This washing process repeated for 3 times and 
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pellet were resuspended in %5 Oligo RPMI-1640 and isolated cells counted by using 
hemocytometer. 
 
2.2.4. Stimulation Assay 
 
2.2.4.1. Cell Number Detection with Cell Count 
After the spleen cells, ocular cells, or peripheral blood mononuclear cells were pooled, 
washed and precipitated, they were suspended in 10 ml of 5% Regular RPMI-1640 media. 
Cells were diluted 10 fold and micropipetted into a hemocytometer. 
The number of cells in the chamber was determined by counting under the light microscope 
from these gridlines as indicated with red areas: 
 
 
 
The cell number was calculated according to the following formula: 
__Cell number__       106    = Total cell number in 10 ml media 
4 
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2.2.4.2. Cell Distribution 
For Cytokine ELISA; 2-4x106/ml cells were distributed into 96 well plates with a final 
volume of 200µl or 250µl media per well. After 6 to 42 hours stimulation supernatants were 
collected from the plates and stored at -20°C. Supernatants were layered to the plates with or 
without diluting for two assay as previously mentioned. 
Cells were splitted into 6 well plates or 15 ml falcons with a final concentration 2-3 
ml, for RNA isolation after stimulation with TLR ligands and/or suppressive ODN for 2 and 4 
hours. 
2.2.4.3. Stimulation with TLR Ligands and/or Supressive ODN 
PBMCs were stimulated with various TLR ligands in optimum doses of: Cont.K23 
ODN; 1uM, CpG ODN K23; 1uM, CpG ODN D35; 1uM, PGN; 1ug/ml, LPS; 0.25 ug/ml, 
pI:C 20ug/ml, R848; 1ug/ml and suppressive ODN A151; 3uM. 
Cells were incubated with 5% Oligo RPMI-1640 when stimulated with ODNs and 
cultured with 5% Regular RPMI-1640 as they stimulated with other TLR Ligands. 
 
2.2.5. Enzyme Linked-ImmunoSorbent Assay 
 
2.2.5.1. Cytokine ELISA 
Polysorp (F96 Nunc-Immunoplate, NUNC, Germany) plates were coated with anti-
cytokine (Pierce, Endogen) mouse or human IL-6 monoclonal antibody ; 10 µg/ml, 5 µg/ml, 
respectively for 4-5 hours at room temperature or overnight at +4°C. Plates were blocked with 
blocking buffer for 2 hours at room temperature and washed with wash buffer for 5 minutes, 5 
times and rinsed with ddH2O. Supernatants and serially diluted recombinant proteins of 
mouse IL-6 (2000 ng/ml) and human IL-6 (1000ng/ml) were added and incubated for 2 hours 
at room temperature or overnight at +4°C. Plates were washed as previously described. For 
the detection of cytokine levels; biotinylated anti-cytokine antibodies (Pierce, Endogen) were 
prepared in a T-cell buffer, 1:1000 dilution, added to the plates and incubated for 2 hours at 
room temperature or overnight at +4°C, followed by washing. 1:5000 diluted SA-AKP was 
prepared in T-cell buffer and added to the plates for 1 hour at room temperature. After 
washing the plates; PNPP substrate was added and after color formation, in three different 
intervals optical densities at target wavelengths were measured on an ELISA plate reader 
(BioTek, µQuant) at 405 nm. The reading was terminated for each plate when an S shaped 
recombinant cytokine standard curve is obtained. 
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Concentrations of the cytokines in supernatants were determined by the 4-parameter 
standard curves generated by using recombinant proteins as mentioned above. 
 
2.2.6. Determination of the Gene Expression 
 
2.2.6.1. Total RNA Isolation from the Cells 
After incubating cells (mouse spleen or human PBMC) with various TLR Ligands 
and/or suppressive ODN A151 for 2 and 4 hours, total RNAs were isolated. The cells were 
scraped and centrifuged at 2500 rpm for 5 min. in cold media. Then the media was removed 
and cells were extensively mixed and homogenated by a mono-phasic solution of phenol and 
guanidinium thiocyanate: TRItidy G. 200 µl of chloroform for every 1ml of TRItidy G was 
used and tubes were vigorously shaken for 15 seconds and incubated at room temperature for 
2-3 mins followed by a centrifugation for 15 mins at 13.900 rpm at 4°C. The aqueous phase 
was transferred to a fresh tube. Total RNA was precipitated by adding 500 µl of 2-propanol 
for every 1ml of TRItidy G, incubated at room temperature for 10 min. and centrifuged for 10 
min. at 13.900 rpm. Next the supernatant was removed and the pellet was washed with 1 ml, 
75% EtOH for every 1 ml of TRItidy G used. Tubes were vortexed and centrifuged at 8000 
rpm for 7 mins in order to remove 2-propanol from the pellet. Supernatant was discharged and 
pellet was washed with 99.9% EtOH, vortexed and centrifuged as previously discussed. After 
centrifugation, the alcohol was removed and pellet was air-dried under laminar flow hood, 
and dissolved with 20-30 µl RNase/DNase free ddH2O. The OD measurements were taken at 
260/280 nm wavelengths using a spectrophotometer (NanoDrop® ND-1000). The expected 
value of the A260/A280 ratio in order to determine if there is a phenol, protein or DNA 
contamination in the RNA samples is between 1.8-2.0 OD. The isolated RNA was stored at -
80°C. 
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2.2.7. cDNA Synthesis 
The cDNAs were synthesized from the total RNA samples with the cDNA synthesis 
kit according to the manufacturers’ protocol. 2µg RNA was mixed with 1µl of Oligo(dT) 
primer and completed to a total volume of 12 µl with RNase/DNase free ddH2O (Hyclone). 
They were pre-denatured at 65°C for 5 min. then chilled on ice for 3-5 min. 15µl RT Buffer 
(includes dNTP mix and 10 mM MgCl2) and 3µl M-MuLV RNase H+ reverse transcriptase 
(includes RNase inhibitor) were added to the mixture and incubated at 25°C for 10 min., 40°C 
for 45 min., 85°C for 5 min. and on ice (+4°C) for 10 min. respectively. cDNA’s were runned 
on %2 Agarose gel for 45-50 min, at 80V and visualized under transilluminator (Gel-Doc 
BIO-RAD, USA and Vilber Lourmat, France) for 1 sec exposure time. The cDNA’s were 
stored at -20°C. 
 
2.2.8. PCR 
 
2.2.8.1. Primers 
Primers such as; il-18, cxcl-16, mip 3-α were designed using Primer3 Input 0.4.0 
program (http://frodo.wi.mit.edu/primer3/input.htm) and Primer Designer 3.0 program with 
the cDNA sequences of the mouse homologues of these genes which are available at     the 
Ensembl database. Each primer pair was blasted (http://www.ncbi.nlm.nih.gov/BLAST/) 
against mouse genome. Other primer sequences were obtained from different articles and 
sources. 
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Table 2.1 The sequences, the product sizes and the sources of the mouse primers used 
     Primer Forward Reverse Product Size 
m β-actin* GTATGCCTCGGTCGTACCA CTTCTGCATCCTGTCAGCAA         450 bp 
m IP10 * GCCGTCATTTTCTGCCTCAT GCTTCCCTATGGCCCTCATT         127 bp 
m iNOS * CAGCTGGGCTGTACAAACCTT CATTGGAAGTGAAGCGTTTCG            95 bp 
mMIP1α ¶ ACCATGACACTCTGCAACCA AGGCATTCAGTTCCAGGTCA            238 bp 
mIL-5 * AGCACAGTGGTGAAAGAGACCTT TCCAATGCATAGCTGGTGATTT           117 bp 
mIL-15 * CATCCATCTCGTGCTACTTGTGTT CATCTATCCAGTTGGCCTCTGT             126 bp 
mIL-18 ¶ GATCAAAGTGCCAGTGAACC ACAAACCCTCCCCACCTAAC             384 bp 
mMCP-1 ¶ AGGTCCCTGTCATGCTTCTG TCTGGACCCATTCCTTCTTG            249 bp 
mMIP3α ¶ CGTCTGCTCTTCCTTGCTTT CCTTTTCACCCAGTTCTGCT            250 bp 
mCXCL16 ¶ CCTTGTCTCTTGCGTTCTTC GGTTGGGTGTGCTCTTTGTT            384 bp 
mMIP1β ¶ CCAGCTCTGTGCAAACCTAA CTGTCTGCCTCTTTTGGTCA            250 bp 
                      
¶ Designed primer 
* An Overview of Real-Time Quantitative PCR: Applications to Quantify Cytokine Gene Expression, 
Giulietti et al., 2001, Methods 
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Table 2.2The sequences, the product sizes and the sources of the human primers used 
     Primer Forward Reverse Product Size 
h GAPDH ACCACCATGGAGAAGGCTGG CTCAGTGTAGCCCAGGATGC       532 bp 
h TLR 1 CATAACTCTGCTGATCGTCACC TGCTAGGAATGGAGTACTGCG'       491 bp 
h TLR 2 GATGACTCTACCAGATGCCTCC CAGAAGAATGAGAATGGCAGC       745 bp 
h TLR 4 TTACCTGTGTGACTCTCCATCC CAGAAGAATGAGAATGGCAGC       507 bp 
h TLR 5 CCTTGACTATTGACA AGGAGGC TTGTAGGCAAGGTTCAGAACC'         713 bp 
h TLR 6 TCTCATGACGAAGGATATGCC' CGATCAGCAGAGTTATGTTGC       578 bp 
h TLR 7 ACGAACACCACGAACCTCAC GGCACATGCTGAAGAGAGTTAC       725 bp 
h TLR 8 TGGCTTGAATATCACAGACGG ACCAGGCAGCATTAATCTTCC       584 bp 
h TLR 10 GAACTGATGACCAAC TGC TCC' GAAGTCTTGATTCCATCACGC       557 bp 
h IL1 β AGATGATAAGCCCACTCTACAG ACATTCAGCACAGGACTCTC       276 bp 
h IL 6 ACAGCCACTCACCTCTTCAG CCATCTTTTTCAGCCATCTTT       168 bp 
h TNF α CCCGAGTGACAAGCCTGTAG GATGGCAGAGAGGAGGTTGAC       271 bp 
 
 
 
2.2.8.2. Semi-Quantitative RT-PCR 
For the comparison of the mRNA expression levels of the samples, semiquantitative 
reverse-transcriptase PCR (MJ Mini, BIO-RAD, USA) was performed. Quantification of the 
band intensities was performed using MultiAnalyst and Bio1D softwares. The quantitated 
values for the samples were normalized by the division with the quantitated values for the β- 
actin for each sample separately. The reaction ingredients used in PCR reactions are shown in 
Table 2.3 and the condition of PCR reactions are shown in Table 2.4 
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Table 2.3 PCR reaction ingredients 
 
 
Reaction Ingredients Volume 
cDNA  1 µl 
DyNAzyme TMII Master Mix (Finnzymes) 12,5 µl 
Forward Primer (Alpha DNA)  1 µl (10 pmol) 
Reverse Primer (Alpha DNA) 1 µl (10 pmol) 
RNase DNase free H2O 9,5 µl 
Total 25 µl 
 
 
 
 
 
 
 
 
Table 2.4: PCR Conditions 
 
 
 
 
 
 
 
PCR conditions used in mouse experiments 
 
94 oC, 30 sec 
55 oC, 30 sec                35 cycles        
72 oC, 1 min. 
 
Final Extension: 10 min. at 72 oC
 
 
 
 
  
94 oC, 10 sec 
65 oC, 20 sec  35 cycles    
     -0.2 oC/cycle                                
 72 oC, 1 min. 
 
PCR conditions used in human experiments 
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 2.2.8.3. Agarose Gel Electrophoresis 
2% agarose gel was prepared with 1X TAE Buffer and 1 mg/ml ethidium bromide 
solution. Samples were prepared by mixing of 5μl Agarose Gel Loading Dye to 10μl of 
cDNA sample and loaded to the agarose gel. The gel was run at 80V for 60 minutes and 
visualized under transilluminator (Gel-Doc BIO-RAD, USA and Vilber Lourmat, France) 
softwares were used to take photographs of the gels and compare the cDNA band intensities 
for the analysis. The, Low Range DNA Ladder (Jena Biosciences) and 100 bp DNA ladder 
(Jena Biosciences) were used as a marker and 3µl was loaded to every gel. 
2.2.9. Statistical Analysis 
 Statistical analysis was done by using SigmaSTAT software significance level 
between untreated (or control groupd) vs treatments were determined via Student’s t- test 
analysis. 
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RESULTS 
 
3.1 ENDOTOXIN INDUCED UVEITIS 
Endotoxin-induced uveitis (EIU) is an established animal model of acute ocular 
inflammation. It is induced by either systemic or intravitreal administration of 
lipopolysaccharide (LPS), the major component of gram-negative bacteria. LPS acts through 
TLR4 triggering proinflammatory signaling cascade. The expression of Th1 cytokines and 
chemokines, including interleukin 6 (IL6), IL-1β, and MIP3α contributes to the development of 
EIU.  
Following local or intraperitonial LPS and/or suppressive ODN administration, rabbit 
and mouse eyes were removed and RNA from iris, vitreous and cornea from rabbit eyes were 
obtained (for mouse total RNA was obtained from the whole eye(s). PCR was run from cDNA 
of each sample and mRNA message of IL1β IL6, IL-15, IL18, IP10, iNOS, MIP1α, MIP1β, 
MIP3α, and CXCL16 levels was monitored. Murine splenocytes were also incubated for 6, 12 
and 24 hrs on 96 well plates in triplicates and IL6 secretion level of the culture media was 
determined by ELISA.  
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Fig.3.1: IL1β induction (as judged by mRNA level via PCR) from uveitic rabbit iris is 
suppressed when the eyes are treated with A151. 
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Results indicate that when suppressive ODN administered before or after LPS treatment 
or included simultaneously with LPS treatment significantly down regulated the expression of 
IL1β message from iris (Fig. 3.1). In cornea, however, only IL6 was downregulated when 
suppressive ODN was given before LPS administration (Fig. 3.2). 
   
 
Fig 3.2: IL6 message is strongly suppressed in cornea of uveitic rabbit eye upon A151 
treatment. 
 
Eventhough it is pricy to conduct rabbit experiment and logistically problemmatic to 
house the animals in a different site instead of our animal facility, the information obtained 
from this set of experiment was critical, because the direct injection of the agent (LPS) to the 
vitreous part of the eye was possible in rabbit system, thus we could induce local EIU at the site 
of the A151 therapy. Another problem associated with the rabbit experiment worth mentioning 
was that, after we have initiated the study we have realized that it was not possible to set the 
best time to retrieve the eye for further investigations. Since LPS mediated inflammation was 
initiated at the vitreous site, it was not possible to deduce when to collect the tissues post-LPS 
treatment. We have decided to sacrifice the animals 24 hrs after the treatment, and check as 
many sites as possible, (i.e. vitreous, iris, and cornea). Data indicated that we have 
unfortunately could not detect any significant change on the gene expression levels of several 
cytokines/chemokines from vitreous region (data not shown). Nevertheless, downregulation of 
the proinflammatory cytokine IL1β and IL6 could be detected from iris and cornea 
respectively.  Instead of repeating rabbit experiment, it was much more reliable to move to 
mouse model.    
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On the murine EIU experiments LPS administrated via i.p. in two different doses; 30 
and 100ug. Supressive ODN (or Control ODN) were given at 250ug and 300ug doses.  
        Naive       LPS(1)   LPS(2)      A151 then LPS(1,2) 
 
Fig.3.3: MIP3α expression level of mouse eyes either injected i.p. with 100µg LPS 
alone or following 250 µg A151 supressive ODN Rx (Numbers in paranthesis indicate the 
number of mice used in the study).  
 
Results showed that when 250ug supressive ODN administered before LPS treatment 
it significantly down regulated the expression of several important Th1 cytokines and 
proinflammatory chemokines  IL18, IP10, iNOS, MIP1α, MIP1β, MIP3α, and CXCL16 in 
100ug LPS injected mEIU model. Of these, MIP3α and iNOS were the most significant down 
regulated mediators. The other cytokines also showed substantial but non significant down 
regulation. (data not shown) 
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Fig 3.4: Suppression of LPS triggered inducible nitric oxide synthase gene by A151 treatment.  
Results demonstrates that when 300ug supressive ODN administered before LPS 
treatment, it significantly down regulated the expression of IP10 and MCP1 in 30ug LPS 
injected mEIU model (data not shown). Results show that when supressive ODN administered 
before or at the same time with LPS treatment it significantly reduced the  IL6 level in mouse 
splenocytes (for 30ug LPS injected experiment). 
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Fig 3.5: Reduction of IL6 production by A151 ODN from murine spleen cells induced by 
LPS 
 
When taken together, these results indicated that rabbit and mouse EIU can be 
reproducibly estaliblished by either parenteral or local administration of LPS, and the disease 
severity and progression at least in part can be controlled by the administration of A151 
suppressive ODN either simultanously or ahead of the insult initiation. 
 
3.2. FAMILIAL MEDITERRANEAN FEVER (FMF)  
FMF is an autosomal recessive periodic fever disease characterized by recurrent, 
self-limiting, febrile, inflammatory attacks of the serosal membranes such as peritoneum, 
pleura, and synovia. FMF patients in clinical remission are reported to have increased baseline 
inflammation. It has been demonstrated that A151 ODN can either neutralize or down 
regulate overexuberant ongoing immune response  and may control local, tissue specific, and 
even certain systemic autoimmune diseases (Zeuner et al., 2002, Dong et al., 2004, Ho et al., 
2003, Yamada et al., 2004). Our preliminary experiments prompted us to focus on FMF as an 
autoinflammatory disease, and use suppressive A151 ODN hoping to neutralize this increased 
baseline inflammation.  
The study was performed on 7 healthy donors and 7 FMF patients. Peripheral blood 
mononuclear cells (PBMC) are isolated from FMF patients and healthy controls. We first 
wanted to establish whether there is a difference between the background TLR (1-10) 
expression between FMF and healthy donors, furthermore we wanted to check the baseline 
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activity of certain proinflammatory  or Th1-based cytokine expression levels (such as IL1β, 
IL6 and TNFα)  by RT-PCR. As seen in figures 3.6 and 3.7 baseline IL1B and IL6 message 
levels were significantly higher in FMF patients compared to healthy donors. This difference 
is more pronounced for IL6. While there is about 2.5 fold difference in the IL1B message 
level of FMF patients to that of healthy subjects, this rose to more than 4 fold for IL6. 
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Fig 3.6: The baseline mRNA level of IL1B is significantly elevated in FMF patients (p<0.01) 
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   Fig 3.7: The baseline mRNA level of IL6 is significantly elevated in FMF patients (p<0.01) 
 
In additon to the cytokine levels, the mRNA from these donors were also checked 
for the expression level of the TLR panel. As seen in Figs 3.8 (A), (B), and (C) for TLR2, 4 
and 7 baseline expression (from unstimulated FMF PBMC) level showed significant mRNA 
message intensities compared to blood taken from unstimulated healthy donor.  
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(C) 
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Fig 3.8: (A) TLR2 expression profiles of unstimulated FMF vs healthy subjects, (B) TLR4 
expression profiles of unstimulated FMF vs healthy subjects, and (C) TLR7 expression 
profiles of unstimulated FMF vs healthy subjects. (p<0.01, for all TLRs) 
 
Initial characterization results indicated that indeed not only there is significantly 
increased baseline inflammation, but certain TLRs (both extracellular and endosome 
associated) have higher TLR2, TLR4, TLR7, levels compared to healthy controls. 
 
These findings encouraged us to stimulate PBMCs with various TLR ligands such as    
i) PGN for TLR2, ii) LPS for TLR4, iii) pI:C for TLR3, and iv) R848 for TLR7/8 either alone 
or in combination with supressive ODN (A151). Cells incubated with those ligands and then 
supernatants were collected 48h after stimulation. Cytokine ELISA was performed to analyse 
the levels of  IL6. As seen in Fig 3.9 , IL6 production in response to TLR2, TLR4, and 
TLR7/8 ligand stimulation by FMF patients induced substantially higher levels of IL6 (to that 
of healthy donors` PBMC).  
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Fig 3.9:  IL6 induction level of healthy and FMF PBMCs. (p<0.01 for LPS and PGN 
groups)   
 
Our data suggest that FMF patients are more sensitive than healthy subjents in terms 
of responding to TLR ligand mediated immune activation. In an attempt to control this 
overexuberant immune activation of FMF patients, supressive ODN, A151 is used in further 
experiments in order to determine whether A151 can supress either the cytokine message or 
cytokine secretion from TLR ligand stimulated healthy and/or FMF patients`  PBMCs. 
Our data revealed that IL1β expression level of healthy donors significantly 
suppressed by suppressive A151 ODN. TLR3, and TLR7/8 but not TLR2 and TLR4 ligands 
mediated IL1β is strongly inhibited by A151 (Fig 3.10). Same level of IL6 suppression was 
seen for IL6 message (Fig 3.11). One striking feature is that this suppression is suppressive 
ODN mediated since treatment with control ODN did not show any effect (data not shown). 
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Fig 3.10. TLR3 and TLR7/8 mediated of IL1b message expression is suppressed by A151. 
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Fig 3.11. TLR mediated IL6 message overexpression is neutralized by treating PBMCs with 
A151. 
The same trend for IL1b and IL6 was repeated for TNFa. Fig 3.12 demonstrate that 
TNFa expression level upon pI:C and R848 induction increased, and this elevated message is 
completely abrogated by the addition of suppressive ODN, A151. These results collectively 
indicate that A151 is strong enough to counteract the proinflammatory activity of TLR3  and 
7/8 ligands.   
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Fig 3.12: TNFa expression is abrogated by A151 when healthy PBMCs were stimulated with 
either TLR3 or TLR7/8 ligands but not with TLR2 or TLR4 ligands.  
Another unexpected observation is that, A151 not only fail to suppress TLR2, and 4 
mediated immune activation, but mixing these ODN with the ligands augments the overall 
immune response (see Figs 3.10, 3.11, and 3.12 for IL1b, IL6 and TNF responses). Fig 3.13 
summarizes the RT-PCR band intensities for Healthy subjects. 
 
Fig 3.13: PCR band intensities for healthy PBMC subject (representative of 5 repeat 
experiments). 
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 Fig 3.14: IL6 secretion form healthy donors upon stimulated with several TLR ligands.  
  
ELISA results showed that A151 supresses the production of IL6 only in pI:C treated 
group. These data indicates that A151 down regulates the expression of  IL6, IL1β and TNFα  
at the mRNA message level for R848 and pI:C treated groups and although IL6 message down 
regulated upon R848 treatment, it could not induce detectable supression on protein level. But, 
in pI:C treated group IL6 down regulated both the message and the protein secretion.  
Later, the supressive effect of A151 tried on FMF patients. PBMCs of the FMF 
patients stimulated with various TLR ligands and/or supressive ODN checked for IL6 levels 
determined by ELISA.  
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Fig 3.15: Lower A151 dose could only suppress pI:C mediated IL6 secretion, but not the rest 
of the tested TLR ligands.  
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Fig 3.16:  Increased A151 treatment dose downregulated IL6 level for pI:C, LPS, PGN but not 
for R848 ligands. (p<0.01 for PGN and LPS alone vs A151plus ligand groups, and p<0.001 for 
pI:C vs A151 plus pI:C group). 
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As shown in the Figs (3.15 and 3.16), A151 down regulated the production of IL6 in a 
dose dependent manner. One patients PBMCs when it is stimulated with LPS, pI:C or PGN. On 
the other hand, in another patient A151 supressed IL6 production only in pI:C stimulated group 
but not the rest.    
It is clear from these data that more patients are needed to enroll in these tests. It is 
challenging and time consuming to obtain several subjects that can be analyzed to establish 
the significance level. We are committed to test more patients and gather reliable data to 
demonstrate the beneficial effect of suppressive DNA on FMF patients.   
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DISCUSSION 
The innate immune response triggered by several TLR ligands can improve host 
survival following pathogen challange. Yet unchecked stimulation of the innate immune 
system can cause tissue damage, autoimmune disease, and even death.  Krieg et al were the 
first to demonstrate that “neutralizing” ODN containing GC-rich sequences selectively 
inhibited CpG-induced immune activation (Krieg et al., 1998).  
 Other G-rich ODN were also shown to block the interaction of CpG ligands with their 
Toll-like receptor (TLR9) (Lenert et al., 2001, Zhu et al., 2002). Subsequently, Gursel et al 
identified a different class of “suppressive” ODN, patterned after the repetitive TTAGGG 
motifs present at high frequency in mammalian telomeres (but rare in the genomes of 
bacteria). Studies showed that these ODN had broad immunosuppressive properties and could 
down-regulate the production of certain Th1 and proinflammatory cytokines (Klinman et al., 
2003, Gursel et al., 2003, Yamada et al., 2002). This led scientists to hypothesize that 
endogenous TTAGGG motifs released by dying host cells might serve to down-regulate 
pathologic/ overexuberant host immune responses (Klinman et al., 2003, Gursel et al., 2003). 
Consistent with such a possibility, suppressive ODN were found to limit the immune 
activation induced by multiple TLR ligands in vitro (Klinman et al., 2003, Zhu et al., 2002). 
In vivo, suppressive ODN ameliorated a variety of organ-specific autoimmune diseases, 
including inflammatory arthritis, rheumatoid arthritis, and EAE (Zeuner et al., 2002, Dong et 
al., 2004, Ho et al., 2003).  
This study establishes that suppressive ODN (typified by ODN A151) is capable of 
suppressing at least in part some features of the Th1 proinflammatory response both in an 
organ specific autoimmune disease model (endotoxin-induced uveitis) and a systemic 
autoinflammatory disease Familial Mediterranean Fever.   
Endotoxin-induced uveitis (EIU) is an animal model of acute ocular inflammation 
induced by the administration of lipopolysaccharide (LPS), a component of Gram-negative 
bacterial outer membranes. Uveitis can have a variety of underlying causes. For instance, 
acute anterior uveitis is often associated with Behcet’s disease, ankylosing spondylitis, 
Reiter’s syndrome, and human leukocyte antigen (HLA) B27-associated uveitis as well as 
other systemic inflammatory diseases (Chang et al., 2005) 
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LPS enhances the expression of various inflammatory mediators, such as IL-6, 
(Hoekzema et al., 1992, Ohta et al., 2005) TNF-α, (Koizimi et al., 2003) and MCP - 1, (Mo et 
al., 1999) as well as the production of nitric oxide (Bellot et al., 1996) all of which contribute 
to the development of EIU, resulting in the breakdown of the blood–ocular barrier and in the 
infiltration of leukocytes. 
The current study demonstrates that systemic or intravitreal administration of 
suppressive ODN down-regulates mRNA message and even production of several 
proinflammatory cytokines both in the eyes and spleen of mouse and rabbit following local or 
intraperitoneal LPS administration.  
Results from rabbit model indicate that when suppressive ODN administered before or 
after LPS treatment or included simultaneously with LPS treatment significantly down 
regulated the expression of IL1β message from iris. In cornea, only IL6 was downregulated 
when supressive ODN was given before LPS administration. 
Results from murine model showed that when supressive ODN administered before 
LPS treatment it significantly neutralized the expression of IP10, iNOS, MIP1α, IL18, MIP3α, 
CXCL16 and MIP1β levels.  Results also suggest that when supressive ODN administered 
before or at the same time with LPS treatment, it significantly down regulated IL6 secretion in 
murine splenocytes. 
Autoinflammatory diseases are a group of disorders characterized by seemingly 
unprovoked inflammation in the absence of high-titer autoantibodies or antigen specific T 
cells (Stojanov et al., 2005). They include the hereditary periodic fever syndromes (HPF) and 
are thought to be caused by disturbances in the regulation of innate immunity (Kastner., 
2005). 
Familial Mediterranean Fever (FMF) is the most well known and best characterized of 
the hereditary periodic fever syndromes. The mutated gene, MEFV, encoding 
pyrin/marenostrin protein, was identified in 1997 and found to be predominantly expressed in 
neutrophils, monocytes and eosinophils but not in lymphocytes (Aksentijevich et al., 1997, 
Bernot et al.,1997), suggesting a potential functional role in the regulation of inflammation.  
Several studies have shown that FMF patients exhibit increased levels of serum IL-6, 
IL-8, IFNγ, IL12, IL18, TNFα (Kiraz et al., 1998, Baykal et al., 2003, Schattner et al., 1991, 
Schattner et al., 1996, Aypar et al., 2003). Gang et al. (1999) measured IL-1β and IL-1 
receptor antagonist levels and suggested that these components are unaltered during attacks 
(Gang et al., 1999). But in another study, mRNA levels for TNF-α, IL-1β, IL-6 and IL-8 were 
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all increased relative to controls in circulating leukocytes of attack-free FMF patients 
(Notarnicola et al., 2002).  
Our preliminary FMF study in accordance with the literature pointed that FMF 
patients have higher IL1β and IL6 expressions, furthermore, current work for the first time 
demonstrate that baseline TLR2, TLR4, TLR7 levels are significantly elevated compared to 
healthy controls. FMF patients are producing more IL6 when they are stimulated with certain 
TLR ligands, (i.e. LPS and PGN), compared to healthy subjects which means FMF patients 
are more sensitive and responsive to these stimulants compared to healthy individuals. A151 
significantly down regulated the expression of IL6, IL1β and TNFα from the PBMCs of 
healthy donors which are stimulated with TLR7/8 and TLR3 ligands, R848 and pI:C. A151 
suppresses pI:C stimulated IL6 production of PBMCs both in FMF patient and healthy donor. 
We observed that suppression of pI:C was more stronger compared to PGN and LPS. There 
seems to be a race between the rate of induction/activation via PGN and LPS and A151 down 
regulatory mechanisms. This observation is supported by the data presented in Figs 3.15 and 
3.16. While low dose A151 could not suppress PGN and LPS in Fig 3.15, it was capable of 
inhibiting LPS and PGN mediated IL6 secretion when A151 dose was raised 2 fold. More 
work is needed to reveal the mechanism underlying behind this phenomenon.  
In conclusion, suppressive ODN A151 inhibits several proinflammatory cytokine 
messages or cytokine production from immune cells. Our data stongly suggest that 
mammalian derived suppressive motifs (A151, telomeric sequence) could be used as a 
therapeutic agent to control either EIU or FMF and might be of use in the treatment of other 
autoimmune or autoinflammatory diseases. 
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APPENDICES 
 
Appendix 1 
 
Standard Solutions, Buffers, Media 
Blocking Buffer (ELISA) 
• 500 ml 1x PBS 
• 25 grams BSA (5%) 
• 250 μl Tween20 (0,025%) 
Crystal particles of BSA should be dissolved very well, with magnetic-heating stirrer for 20-
30 min. The buffer should be stored at -20°C. 
Loading Dye (Agarose gel) 
• 0,009 grams Bromofenol blue  
• 0,009 grams Xylen cyanol  
• 2,8 ml ddH2O 
• 1,2 ml 0,5M EDTA 
• 11 ml glycerol 
After preparing, just vortex it. 
PBS (Phosphate Buffered Saline) [10x] 
• 80 grams NaCl 
• 2 grams KCl 
• 8,01 grams Na2HPO4 . 2H2O 
• 2 grams KH2PO4 
into 1 lt ddH2O 
pH= 6,8. For 1xPBS’s pH should be ≈ 7,2-7,4. Should be autoclaved prior to use. 
 
TAE (Tris-Acetate-EDTA) [50x] 
• 242 grams Tris (C4H11NO3) 
• 37,2 grams Tritiplex 3 (EDTA= C10H14N2Na2O2 . 2H2O) 
• 57,1 ml Glacial acetic acid 
into 1 lt ddH2O 
Dissolves in ≈1 day. Should be autoclaved. Diluted to 1X prior to use 
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T-cell Buffer [ELISA] 
• 500 ml 1x PBS 
• 25 ml FBS (5%) 
• 250 μl Tween20 (0,025%) 
The buffer should be stored at -20°C. 
 
Wash Buffer [ELISA] 
• 500 ml 10x PBS 
• 2,5 ml Tween20   
• 4,5 lt dH2O 
High Glucose DMEM (Hyclone) and RPMI-1640 (Hyclone) 
• 2 %: 10 ml FBS (OLIGO FBS = inactivated at 65°C, Regular FBS = inactivated at 
55°C ) 
• 5 % : 25 ml FBS 
• 10 % : 50 ml FBS 
• 5 ml Penicillin/Streptomycin (50 µg/ml final concentration from 10 mg/ml stock) 
• 5 ml HEPES (Biological Industries), (10 mM final concentration from 1M stock ) 
• 5 ml Na Pyruvate, (0,11 mg/ml final concentration from 100mM, 11 mg/ml stock) 
• 5 ml Non-Essential Amino Acids Solution, (diluted into 1x from 100x concentrate 
stock) 
• 5 ml L-Glutamine, (2 mM final concentration from 200 mM, 29.2 mg/ml stock) 
In 500 ml media 
 
NaNO2 (100µM) 
• 34,5 µg NaNO2  
• 50 ml Ultrapure H2O [100x] 
Dilute this solution into 1x for 100µM concentration. 
 
 
 
 
 
 
